TY - T1的光谱学先生在多发性硬化疾病进展的标志:一个临床验证研究(PL01.002) JF -神经学乔-神经病学SP - PL01.002 LP - PL01.002六世- 78 - 1补充AU -萨拉Llufriu AU -约翰Kornak AU -首页海伦Ratiney盟Joonmi哦AU -唐Brenneman盟Mehul Sampat盟——斯蒂芬·豪泽盟——莎拉·纳尔逊AU -库马拉斯Srinivasan盟丹尼尔Pelletier Y1 - 2012/04/25 UR - //www.ez-admanager.com/content/78/1_Supplement/PL01.002.abstract N2 -目的:验证特定体内标记先生的预测价值中枢神经系统(CNS)损伤的脑容量损失随着时间的推移和临床残疾在多发性硬化症(MS)。背景预测长期残疾变得必要优化治疗决策和提高风险/受益。病理损伤中枢神经系统包括髓鞘脱失,女士neuro-axonal损失,astrogliosis,所有这些可以使用髓水体内评估分数(MWF) N-acetylaspartate (NAA)和肌醇(mI)成像,分别。设计/方法:322名调查对象参加了这个实验。基线NAA和mI怀特女士(MSWM)和灰质(MSGM),并从MSWM MWF进行评估预测在训练数据集(n = 59女士,n = 43控制)。的重要预测因子,随后被测试复现性的验证数据集(n = 220 MS)。eds、所有分数和百分比的大脑体积变化(PBVC)获得了4年每年在这两个数据集。统计分析了使用mixed-effects和多元回归建模。结果:NAA和mI显著统计影响脑容量的训练数据集提出考虑mI / NAA MSWM比率作为主要指标。比在两个数据集的基线预测PBVC([每年-1.67%;p = 0.017]和[每年-1.03%;p = 0.02),分别)。 In addition, the ratio predicted MSFC outcomes; linear MSFC evolution (-0.52 annually; P<0.001); MSFC sustained progression (Odds Ratio of 2.76; p=0.013) in the training dataset. Linear MSFC evolution findings were replicated in the confirmatory dataset (-0.23 annually; p=0.012). Lastly, mI/NAA [MSWM] ratio predicted EDSS evolution (0.57 annually; p=0.04) and EDSS sustained progression (Odds Ratio of 1.46; p=0.009) in the confirmatory dataset.Conclusions: The combined presence of astrogliosis and axonal damage has a cardinal importance in MS progression. mI/NAA ratio has consistent predictive power in the evolution of brain atrophy and disability. Its practicality as a ratio makes it suitable for clinical use.Supported by: Grants from the U.S. NMSS (JF 2122-A, training dataset) and the NIH/NINDS (R01-NS062885, confirmatory dataset).Disclosure: Dr. Llufriu has received personal compensation for activities with Merck Serono and Biogen Idec as a speaker. Dr. Kornak has nothing to disclose. Dr. Ratiney has nothing to disclose. Dr. Oh has received personal compensation for activities with Fynarc. Dr. Brenneman has nothing to disclose. Dr. Sampat has nothing to disclose. Dr. Hauser has received personal compensation for activities with BioMarin, Novartis and Receptos as a consultant and serving on a scientific advisory board.Dr. Hauser has received personal compensation in an editorial capacity for the journal Annals of Neurology and Harrison's Internal Medical textbook.Dr. Hauser has received compensation for serving on the scientific advisory board of Receptos. Dr. Nelson has nothing to disclose. Dr. Srinivasan has nothing to disclose. Dr. Pelletier has received personal compensation for activities with Teva Neuroscience, Genetech, Biogen-Idec, Bayer, and Synarc Inc. Dr. Pelletier has received research support from Biogen Idec.Wednesday, April 25 2012, 09:00 am-12:00 pm ER -